Lucid Diagnostics Q4 Earnings Call Highlights
Lucid Diagnostics (NASDAQ: LUCD) reported higher fourth-quarter 2025 EsoGuard testing volume and revenue and highlighted progress on reimbursement initiatives, including a new U.S. Department of Veterans Affairs (VA) contract and ongoing discussions with Medicare and commercial payers. Fourth-quarter test volume exceeded company's target range Chairman and CEO Dr. Lishan Aklog said fourth-quarter EsoGuard test volume totaled
Open original source